COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #41 of 231
5/18 Late treatment study
Kim et al., medRxiv, doi:10.1101/2020.05.13.20094193 (Preprint)
Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea
Source   PDF   Share   Tweet
Retrospective of 97 moderate cases. Time to viral clearance significantly shorter for HCQ+antibiotic. Preprint withdrawn pending peer review.

Kim et al., 5/18/2020, retrospective, South Korea, Asia, preprint, 11 authors.
hospitalization time, 51.0% lower, relative time 0.49, p = 0.01, treatment 22, control 40.
time to viral-, 56.0% lower, relative time 0.44, p = 0.005, treatment 22, control 40.
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.